Top

Published in:

01-03-2009 | Original Paper

Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger

Authors: Rita Bori, Gábor Cserni

Published in: Pathology & Oncology Research | Issue 1/2009

Abstract

Breast cancer in the young is considered a special clinical presentation of the disease. Sixty-nine breast cancer cases diagnosed at or before the age of 35 were analyzed for common morphological and immunophenotypical features of basal-like carcinomas. Sixteen carcinomas displayed the immunophenotypical characteristics (estrogen receptor and HER2 negativity and positivity for at least one of the following basal markers: cytokeratin 5 or 14, epidermal growth factor receptor, p63) of basal-like carcinomas, and most of them demonstrated characteristic histological features (pushing borders, lymphocytic peritumoral infiltrate, central hypocellular zone or necrosis, high mitotic rate) too. These tumors were more likely to be high-molecular-weight cytokeratin: 34betaE12 and p53 positive by immunohistochemistry. The presence of a basal-like phenotype can be important as concerns systemic treatment issues and could theoretically be associated with a higher rate of BRCA1 mutations in the young, because of the overlap of BRCA1 mutation associated breast carcinomas and the basal-like phenotype.

Fernandopulle SM, Cher-Siangang P, Tan PH (2006) Breast carcinoma in women 35 years and younger: a pathological study. Pathology 38:219–222PubMedCrossRef

Figueiredo JC, Ennis M, Knight JA et al (2007) Influence of young age at diagnosis and family history of breast or ovarian cancer on breast cancer outcomes in a population-based cohort study. Breast Cancer Res Treat 105:69–80PubMedCrossRef

Armes JE, Egan AJ, Southey MC et al (1998) The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 83:2335–2345PubMedCrossRef

Bennett IC, Freitas R Jr, Fentiman IS (1991) Diagnosis of breast cancer in young women. Aust N Z J Surg 61:284–289PubMedCrossRef

Tai P, Cserni G, Van de Steene J et al (2005) Modeling the effect of age in T1-T2 breast cancer using the SEER database. BMC Cancer 5:130. doi:10.1186/1471-2407-5-130 PubMedCrossRef

Trecate G, Vergnaghi D, Manoukian S et al (2006) MRI in the early detection of breast cancer in women with high genetic risk. Tumori 92:517–523PubMed

Golshan M, Miron A, Nixon AJ (2006) The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 192:58–62PubMedCrossRef

Lubiński J, Górski B, Huzarski T et al (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71–76PubMedCrossRef

Loizidou M, Marcou Y, Anastasiadou V et al (2007) Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. Clin Genet 71:165–170PubMedCrossRef

10.

Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835PubMedCrossRef

11.

Foulkes WD, Metcalfe K, Sun P et al (2004) Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type. Clin Cancer Res 10:2029–2034PubMedCrossRef

12.

Laakso M, Loman N, Borg A et al (2005) Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol 18:1321–1328PubMedCrossRef

13.

Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11:5175–5180PubMedCrossRef

14.

Lidereau R, Eisinger F, Champeme MH et al (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60:1206–1210PubMed

15.

Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMed

16.

Fulford LG, Easton DF, Reis-Filho JS et al (2006) Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 49:22–34PubMedCrossRef

17.

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98:10869–10874PubMedCrossRef

18.

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100:8418–8423PubMedCrossRef

19.

Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374PubMedCrossRef

20.

Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728PubMedCrossRef

21.

Rakha EA, El-Sayed ME, Green AR et al (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32PubMedCrossRef

22.

Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRef

23.

Ellis IO, Pinder SE, Bobrow L et al (2005) Pathology reporting of breast disease. NHS Publication No 58. Sheffield: NHS Cancer Screening Programmes and the Royal College of Pathologists. Accessed at 12 July 2007. http://www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp58-low-resolution.pdf

24.

DakoCytomation. HercepTestTM, 8th ed. Accessed at 12 July 2007. http://dist.dako.com/prod_downloadpackageinsert.pdf?objectid=105073005

25.

Takei H, Iino Y, Horiguchi J et al (1997) Low and high molecular weight cytokeratins in invasive breast carcinoma. Oncol Rep 4:33–38

26.

Ridolfi RL, Rosen PP, Port A et al (1977) Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 40:1365–1385PubMedCrossRef

27.

Tot T (2000) The cytokeratin profile of medullary carcinoma of the breast. Histopathology 37:175–181PubMedCrossRef

28.

Jacquemier J, Padovani L, Rabayrol L et al (2005) Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 207:260–268PubMedCrossRef

29.

Reis-Filho JS, Milanezi F, Steele D et al (2006) Metaplastic breast carcinomas are basal-like tumours. Histopathology 49:10–21PubMedCrossRef

30.

Tsuda H, Takarabe T, Hasegawa F et al (2000) Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 24:197–202PubMedCrossRef

31.

Bratthauer GL, Miettinen M, Tavassoli FA (2003) Cytokeratin immunoreactivity in lobular intraepithelial neoplasia. J Histochem Cytochem 51:1527–1531PubMed

32.

van ’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536PubMedCrossRef

33.

Banerjee S, Reis-Filho JS, Ashley S et al (2006) Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J Clin Pathol 59:729–735PubMedCrossRef

Title: Basal Phenotype in Breast Carcinoma Occurring in Women Aged 35 or Younger
Authors: Rita Bori
Gábor Cserni
Publication date: 01-03-2009
Publisher: Springer Netherlands
Published in: Pathology & Oncology Research / Issue 1/2009
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-008-9090-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Quantification of Dendritic Cells and Osteoclasts in the Bone Marrow of Patients with Monoclonal Gammopathy

A Case of Osteoclast-like Giant Cell Tumor of the Pancreas Associated with Borderline Mucinous Cystic Neoplasm

Immunohistochemical Evaluation of 95 Bone Marrow Reactive Plasmacytoses

Cysticercosis of the Fourth Ventricle Causing Sudden Death: A Case Report and Review of the Literature

RETRACTED ARTICLE: Poly(Adenosine Diphosphate-Ribose) Polymerase-1 Expression in Cutaneous Malignant Melanomas as a New Molecular Marker of Aggressive Tumor

The Potential of Digital Microscopy in Breast Pathology

Keynote webinar | Spotlight on antibody–drug conjugates in cancer